Abstract Up to 30% of acute myeloid leukemia (AML) patients face unfavorable outcomes due to the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Although FLT3 inhibitors show encouraging outcomes in treatment. they fail to eliminate leukemia stem cells. the origin of persistent and resistant lesions. https://www.adventuresonabike.com/product-category/spray-per-ambiente/